Tanemura et al. determined that RASSF1A methylation was present in nearly 50% of stage IV melanoma compared to no methylation in stages I and II; this indicates that RASSF1A could signify progression and prognosis in melanoma, but further studies must explore this further [83]. The gene discussed is RASSF1; the disease is melanoma.